NOV/CCN3 Antibody (209808) [Alexa Fluor® 700]

• Applications: WB
• Clone: 209808
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

NOV/CCN3 Antibody (209808) [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human NOV/CCN3
  Thr32-Met357
  Accession # P48745
• Specificity: Detects human NOV/CCN3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross-react with recombinant mouse NOV, recombinant human (rh) CTGF, or rhWISP-1.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

NOV, also called CCN3, is one of six CCN (CYR61/CTGF/NOV) secreted proteins which share a common multimodular organization (1 - 4). NOV/CCN3 contains an N-terminal IGFBP domain that appears to be non-functional and a vWF type C and thrombospondin type I domain which mediate oligomerization and matrix interactions, respectively (1, 2). The C-terminal cysteine knot domain interacts with several partners, including the matrix protein fibulin 1C (5), Notch-1 (6), and CCN2, with which it may heterodimerize (2). NOV/CCN3 also interacts with the gap junction protein Connexin43 and mediates suppression of proliferation (7). It also binds the calcium binding protein S100A4 and promotes calcium channel activation (8). The 357 amino acid (aa), 44 kDa human NOV/CCN3 shares 80% aa identity with mouse, rat and dog NOV/CCN3, and 78% aa identity with cow NOV/CCN3. NOV/CCN3 also shows 38 - 50% aa identity with other family members including WISP proteins, except for WISP-2/CCN5 which lacks the cysteine knot (1). NOV/CCN3 is widely expressed developmentally, especially in muscle, endothelium, nervous system, adrenal cortex and chondrocytes (1 - 4). In transformed cells, a 32 kDa N-terminally truncated form lacks the signal sequence is localized to the nucleus. Truncation allows a C-terminal nuclear localization sequence to be active (9). Nuclear NOV/CCN3 acts as a transcriptional repressor but promotes proliferation, presumably by interfering with growth control (9). Full length NOV/CCN3 is a secreted matricellular protein which inhibits cell growth. Interaction of NOV/CCN3 with integrins alpha _v beta ₃ and  alpha ₅ beta ₁ mediates endothelial cell adhesion, chemotaxis, and promotes angiogenesis (10, 11). Over-expression of NOV/CCN3 downregulates myogenic genes such as MyoD (12).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for NOV/CCN3 Antibody (FAB1640N). (Showing 1 - 1 of 1 FAQ).

1. I am looking for the expression of CCN3/NOV in tumor cells and I am interested in finding an antibody that has a lot of data to support the antibody is working well. Can you make a recommendation?
   • We have two antibodies, NBP1-88154 and NBP1-88155 that have been extremely well characterized by testing at the Human Protein Atlas. Please see the Human Protein Atlas website for full testing for these products.